PharmaShots Weekly Snapshot (May 13–17, 2019)


1. Roche Signs a Worldwide License Agreement with Parvus Therapeutics to Develop and Commercialize Navacim Platform for Autoimmune Diseases

Published: May 16, 2019 | Tags: Roche, Signs, Worldwide, License, Agreement, Parvus Therapeutics, Develop, Commercialize, Navacim Therapeutics, Autoimmune Diseases

2. Exelixis Signs an Exclusive Option and License Agreement with Iconic Therapeutics for Advancing ADC Program

Published: May 16, 2019 | Tags: Exelixis, Signs, Exclusive, Option, License, Agreement, Iconic Therapeutics, Advancing, ADC Program

3. Pfizer’s Fragmin (dalteparin sodium) Receives FDA’s Approval for Symptomatic Venous Thromboembolism in Pediatric Patients

Published: May 16, 2019 | Tags: Pfizer, Fragmin, dalteparin sodium, Receives, FDA, Approval, Symptomatic Venous Thromboembolism, Pediatric Patients

4.Thermo Fisher to Acquire Manufacturing Facility from GSK for ~$100M

Published: May 16, 2019 | Tags: Thermo Fisher, Acquire, Manufacturing Facility, GSK, ~$100M

5. Sanofi and Regeneron Report Updated Results of Libtayo (cemiplimab-rwlc) in P-II EMPOWER-CSCC-1 Study for Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma

Published: May 16, 2019 | Tags: Sanofi, Regeneron, Report, Updated, Results, Libtayo, cemiplimab-rwlc, P-II, EMPOWER-CSCC-1, Study, Locally Advanced, Metastatic, Cutaneous Squamous Cell Carcinoma

6. GSK Expands its License Agreement with Zymework to Develop and Commercialize Bi-Specific Antibodies

Published: May 16, 2019 | Tags: GSK, Expands, License Agreement, Zymework, Develop, Commercialize, Bi-Specific Antibodies

7.NeuClone to Initiate P-I Clinical Study of Stelara (ustekinumab, biosimilar) in Australia

Published: May 15, 2019 | Tags:NeuClone, Initiate, P-I, Clinical Study, Stelara, ustekinumab, biosimilar, Australia

8. Takeda and Frazier Healthcare Collaborate to Launch a Facility Phathom Pharmaceutical for Gastrointestinal Disorders

Published: May 15, 2019 | Tags: Takeda, Frazier Healthcare, Collaborate, Launch, Facility, Phathom Pharmaceuticals, GI disorders

9.Roche and AbbVie’s Venclexta (venetoclax) + Gazyva (obinutuzumab) Receive FDA’s Approval for Untreated Chronic Lymphocytic Leukemia

Published: May 16, 2019 | Tags: Roche, AbbVie, Venclexta, venetoclax, Gazyva, obinutuzumab, Receive, FDA, Approval, Untreated, Chronic, Lymphocytic Leukemia

10. Vertex Signs a 4 Years Agreement with Kymera to Discover and Develop Protein Degradation Therapies

Published: May 15, 2019 | Tags: Vertex, Signs, 4years, Agreement, Kymera, Discover, Develop, Protein Degradation Therapies

11.REGENXBIO Launches a Manufacturing Facility for Developing Gene Therapies Based on NAV-Technology

Published: May 15, 2019 | Tags: REGENXBIO, Launches, Manufacturing Facility, Developing, Gene Therapies, Based, NAV-Technology

12. Progenics Signs an Exclusive Agreement with ROTOP Pharmaka to Develop and Commercialize Imaging Agent 1404 for Prostate Cancer in Europe

Published: May 14, 2019 | Tags: Progenics, Signs, Exclusive, Agreement, ROTOP, Pharmaka, Develop, Commercialize, Cancer Imaging Agent, 1404, Prostate Cancer, Europe

13. Abbott Collaborates with NIH on Brain Initiative for Advancing Research on Neurological Disorders

Published: May 14, 2019 | Tags: Abbott, Collaborates, NIH, Brain Initiative, Advancing, Research, Neurological Disorders            

14. Merck KGaA and Pfizer’s Bavencio (avelumab) + Inlyta (axitinib) Receive FDA’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Published: May 14, 2019 | Tags: Merck KGaA, Pfizer, Bavencio, avelumab, + Inlyta, axitinib, Receive, FDA, Approval, 1L, Treatment, Advanced, Renal Cell Carcinoma

15. Myovant Sciences Reports Results of Relugolix Combination Therapy in P-III LIBERTY 1 Study for Uterine Fibroids in Women

Published: May 14, 2019 | Tags: Myovant Sciences, Reports, Results, Relugolix Combination Therapy, P-III LIBERTY 1, Study, for Uterine Fibroids, Women

16.AliveCor’s KardiaMobile 6L Receives FDA’s Clearance as Six-Lead Personal ECG Device

Published: May 13, 2019 | Tags: AliveCor, KardiaMobile 6L, Receives, FDA, Clearance, Six-Lead, Personal, ECG Device

17. HanX Biopharmaceuticals Signs a License Agreement with Onconova to Develop and Commercialize Rigosertib in Greater China

Published: May 13, 2019 | Tags: HanX, Signs, License, Agreement, Onconova, Develop, Commercialize, Rigosertib, Greater China

18. Exelixis and Daiichi Report Launch of Minnebro (Esaxerenone) Tablets for Hypertension in Japan

Published: May 13, 2019 | Tags: Exelixis, Daiichi, Report, Launch, Minnebro, Esaxerenone Tablets, Hypertension, Japan

19.Regeneron’s Eylea (aflibercept) Injection Receives FDA’s Approval for Diabetic Retinopathy

Published: May 13, 2019 | Tags: Regeneron, Eylea, aflibercept, Injection, Receives, FDA, Approval, Diabetic Retinopathy

20. Roche Launches Cobas MTB-RIF/INH Test for the Detection of Antimicrobial Resistance in Tuberculosis

Published: May 14, 2019 | Tags: Roche, Launches, Cobas MTB-RIF/INH Test, Detection, Antimicrobial Resistance, Tuberculosis

21.The US FDA Issues Final Guidance on Interchangeable Biosimilars

Published: May 10, 2019 | Tags: The US FDA, Issues, Final Guidance, Interchangeable Biosimilars

22. Boston Scientific Reports Results of Emblem S-ICD System in UNTOUCHED Study to Prevent Sudden Cardiac Death

Published: May 10, 2019 | Tags: Boston Scientific, Reports, Results, Emblem S-ICD System, UNTOUCHED, Study, Prevent, Sudden, Cardiac Death

23. Novartis Voluntary Nationwide Recalls Three Lots of Promacta (eltrombopag, 12.5 mg) Oral Suspension Due to Peanut Contamination

Published: May 11, 2019 | Tags: Novartis, Voluntary, Nationwide, Recalls, Three, Lots, Promacta, 12.5mg, Oral Suspension, Peanut Contamination

24. Eli Lilly’s Cyramza (ramucirumab) Receives FDA’s Approval as a Second-line Treatment in Patients with High AFP Hepatocellular Carcinoma

Published: May 10, 2019 | Tags: Eli Lilly, Cyramza, ramucirumab, Receives, FDA, Approval, Second line, Treatment, Patients, High AFP, Hepatocellular Carcinoma

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post